After CRL, CorMedix says new filing has been accepted by FDA; Spine BioPharma nets a modest Series B
After a manufacturing slip-up led to a CRL last year, a small biotech says its new approach is ready for the FDA.
NJ-based CorMedix …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
